Jennison Associates
AUTL

Jennison Associates’s Autolus Therapeutics AUTL Stock Holding History

Jennison Associates’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-106,971
Closed -$3.51M – 635
2018
Q4 		$3.51M Sell
106,971
-12,219
-10% -$402K ﹤0.01% 492
2018
Q3 		$3.6M Buy
119,190
+947
+0.8% +$25.6K ﹤0.01% 507
2018
Q2 		$3.17M Buy
+118,243
New +$3.12M ﹤0.01% 514

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jennison Associates's AUTL Position: Q1 2019 in Review

Jennison Associates sold out of Autolus Therapeutics (AUTL) in Q1 2019, closing a stake of 106,971 shares — an estimated $3.51M sold.

Jennison Associates first reported a position in AUTL in Q2 2018 and held it in 3 quarters. The position peaked at $3.6M in Q3 2018. 35 funds tracked by Wall St. Rank hold AUTL as of Q1 2019.

  • Jennison Associates reported no remaining Autolus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Jennison Associates sold 106,971 Autolus Therapeutics shares in Q1 2019, an estimated $3.51M.
  • Jennison Associates first reported a position in Autolus Therapeutics in Q2 2018 and held it in 3 quarters.
  • Jennison Associates's Autolus Therapeutics position peaked at $3.6M in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2019.

Based on Jennison Associates's 13F filing for Q1 2019, filed 10 May 2019.